Nexplanonetonogestrel
According to the FDA label: NEXPLANON ® is indicated for prevention of pregnancy in women of reproductive potential for up to 5 years. NEXPLANON is a progestin indicated for prevention of pregnancy in women of reproductive potential for up to 5 years. ( 1 )
47,183 adverse event reports submitted to the FDA (2004–2026)
Top Reported Adverse Events
The most frequently reported events in association with Nexplanon in the FAERS database. These are events reported by patients taking this medication, not necessarily caused by it. A single report may include multiple events.
Show these terms with plain-language definitions
Tap any term below for a plain-language definition.
No Adverse Event 9,910 reports
A report that was filed but did not actually describe any adverse event. This is a record-keeping category.
Full definition in the glossary →Product Quality Issue 5,554 reports
A report of a possible problem with the medication's quality, such as appearance, packaging, or condition. This is a quality-tracking category.
Full definition in the glossary →- Complication Associated With Device 5,258 reports
- Device Difficult To Use 4,563 reports
- Device Breakage 4,507 reports
- Incorrect Product Administration Duration 3,656 reports
- Unintended Pregnancy 3,540 reports
- Device Deployment Issue 3,372 reports
- Complication Of Device Removal 3,280 reports
- Complication Of Device Insertion 3,249 reports
- Pregnancy With Implant Contraceptive 3,237 reports
- Device Dislocation 2,669 reports
- Implant Site Pain 2,578 reports
- Menorrhagia 2,443 reports
Vaginal Haemorrhage 2,307 reports
Vaginal bleeding, particularly heavy or unexpected bleeding. Also spelled hemorrhage in American English.
Full definition in the glossary →
Ranked by frequency of reports, not severity. The most-reported event is not necessarily the most dangerous or the most common in patients taking this drug.
Who Is Reporting
Demographics of patients in FAERS reports that included this information. Not all reports include patient demographics.
By Sex
View reporter sex data as a table
| Sex | Reports |
|---|---|
| Female | 44,641 |
| Unknown | 696 |
| Male | 82 |
By Age Group
View age group data as a table
| Age group | Reports |
|---|---|
| 0-17 | 3,198 |
| 18-34 | 18,748 |
| 35-49 | 2,945 |
| 50-64 | 107 |
| 65-74 | 4 |
| 75+ | 4 |
This shows who filed reports, reflecting who takes this drug and who tends to report, not who is at greatest risk.
Reported Outcomes
Outcomes recorded in FAERS reports that included Nexplanon. A single report may involve multiple reactions, each with a different outcome. These categories are defined by FDA reporting guidelines, not by PillSignal.
View outcome data as a table
| Outcome | Reports |
|---|---|
| Non-Serious | 33,858 |
| Other Serious | 11,976 |
| Hospitalization | 1,660 |
| Disability | 697 |
| Life-Threatening | 397 |
| Death | 97 |
Serious outcomes are far more likely to be reported than mild ones, so this overstates how often outcomes are serious. A recorded death does not mean the drug caused it.
Report Volume Over Time
Number of FAERS reports received per quarter for Nexplanon. Changes in volume may reflect shifts in prescribing rates, media attention, or reporting behavior, not changes in the medication's safety profile.
View report trend as a table
| Year | Reports |
|---|---|
| 2004 | 1 |
| 2006 | 34 |
| 2007 | 88 |
| 2008 | 56 |
| 2009 | 56 |
| 2010 | 3 |
| 2011 | 55 |
| 2012 | 619 |
| 2013 | 2,766 |
| 2014 | 3,778 |
| 2015 | 4,243 |
| 2016 | 4,828 |
| 2017 | 4,427 |
| 2018 | 4,941 |
| 2019 | 4,845 |
| 2020 | 3,976 |
| 2021 | 3,816 |
| 2022 | 3,503 |
| 2023 | 1,626 |
| 2024 | 1,477 |
| 2025 | 1,814 |
| 2026 (partial) | 231 |
The steep increase around 2004 reflects the FDA's move to electronic submission, not a change in this drug's safety. Trends track reporting volume, not risk.
Related Drugs
Other medications with similar adverse event profiles in FDA FAERS reports.
Data Source
This data is sourced from the FDA's Adverse Event Monitoring System (AEMS), formerly FAERS, via the OpenFDA API. PillSignal is not affiliated with the FDA.
View this data on the FDA website →Data last updated: June 2026